Log in or Sign up for Free to view tailored content for your specialty!
Polymyositis News
Bone-safe glucocorticoid dose ‘hard to find’ in rheumatic, musculoskeletal diseases
PHILADELPHIA — A daily glucocorticoid dose higher than 2.5 mg may lead to irreversible bone mineral density loss regardless of intervention with osteoporosis medications, according to data presented at ACR Convergence 2022.
Rituximab ‘should be considered’ an alternative to cyclophosphamide in CTD-ILD
PHILADELPHIA — Rituximab is comparable in terms of safety and efficacy to cyclophosphamide among patients with interstitial lung disease associated with connective tissue diseases, according to data presented at ACR Convergence 2022.
Log in or Sign up for Free to view tailored content for your specialty!
Dermatomyositis among high risk factors for cancer in idiopathic inflammatory myopathy
PHILADELPHIA — High risk factors for cancer in patients with idiopathic inflammatory myopathy include dermatomyositis, anti-TIF1-gamma positivity, anti-NXP2 positivity and age 40 or older at onset, said a speaker here.
Apremilast may be safe, efficacious option in recalcitrant cutaneous dermatomyositis
Apremilast may be an efficacious and safe treatment option for patients with recalcitrant cutaneous dermatomyositis, according to a study.
JAK inhibition ‘promising,’ could reduce steroid use in dermatomyositis
Earlier this year, a group of researchers published data from long-term extension study of tofacitinib in patients with dermatomyositis, demonstrating a “sustained response” to a pan-JAK inhibitor in this population.
‘Poorly understood’ and rife with mimics: Rheum-neuro diseases require a team approach
For all the multitudes of diseases and diversity of organ systems rheumatologists are adept at managing and analyzing, the brain, spinal cord and related neurological conditions are often not among them.
Polymyositis diagnoses ‘exceedingly rare’ in shift toward inclusion body myositis
SAN DIEGO — Many patients who might have previously been diagnosed with polymyositis are now being treated for inclusion body myositis, according to a speaker at the Congress of Clinical Rheumatology West.
Humira biosimilar approval paused after FDA finds ‘deficiencies’ at manufacturing facility
The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.
Patients with autoimmune disease receiving ICI exhibit better survival vs. controls
Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.
Myositis pain strategies ‘not uniform,’ require ‘multiple modalities’
Among patients with myositis, younger individuals with dermatomyositis are more likely to experience pain, while those with polymyositis are more likely to receive opioids, according to data published in Rheumatology.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read